Bao Pharma-B (02659) Surges Over 15% in Early Trading on Strong Clinical and Commercial Milestones

Shares of Shanghai Bao Pharmaceuticals Co., Ltd. (BAO PHARMA, stock code: 02659) climbed more than 15% in early Hong Kong trading on Wednesday, as the biotech firm signaled steady progress across its lead clinical programs and a fresh product launch that together mark a pivotal stretch in its commercial roadmap.

As of the morning session, the stock was up 8.10% at HK$12.55, with turnover of about HK$7.38 million (HK$7,384,700), according to market data. The rally came as investors digested a wave of updates on the company's pipeline, centered on two flagship products — KJ103 and KJ017 — that are advancing through late-stage trials and onto the market.

The biggest catalyst appears to be KJ103, a therapy aimed at desensitization treatment before kidney transplantation. A New Drug Application for the product was submitted in mainland China in May 2026 and has since been accepted by the National Medical Products Administration, a milestone that puts the drug on the doorstep of regulatory approval.

In a separate readout, a Phase 3 clinical trial of KJ103 for desensitization in highly sensitized kidney transplant patients reached its primary endpoint in March 2026. The company said the results showed rapid desensitization with a high success rate and a favorable safety profile — a combination that, if borne out in fuller data, could give the drug a meaningful edge in a patient population where transplant options are otherwise limited.

Bao Pharma is also pushing KJ103 into rarer kidney indications. Phase 2 clinical data for the drug in anti-GBM disease were presented at the European Renal Association Congress in June 2026, with the company saying the findings offered an early read on the therapy's clinical value in the space.

On the commercial side, the company's other lead product, KJ017, received regulatory approval in China in March 2026 for use as an adjunct in subcutaneous infusion. Data from two Phase 3 studies of the product were published in the European Journal of Pharmaceutics and Biopharmaceutics, bolstering the clinical evidence base that Bao Pharma is leaning on as it courts partners.

That partnership push is gaining traction. As of the company's mid-2026 interim report, more than 60 partners are using KJ017 in product development, with projects spanning stages from early-stage research through clinical development — a sign that the drug is becoming a platform asset rather than a one-off launch.

For Bao Pharma, the morning's stock move reflects a market reassessing the odds that a mid-cap biotech can deliver on multiple fronts at once: a near-term NDA acceptance, clean Phase 3 readouts, an approved launch, and a growing partner network. The question now is whether the company can convert that clinical momentum into sustained revenue — and whether the rally has more room to run.